MIRM vs ACA Comparison

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Arcosa Inc is a manufacturer and producer of infrastructure-related products and solutions in the U.S. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. Maximum revenue is generated from the Construction Products segment, which produces aggregates, specialty materials, asphalt, and construction support gear. The Engineered Structures segment mainly manufactures and sells steel and concrete structures for infrastructure businesses, including utility structures for electricity transmission and distribution, structural wind towers, traffic and lighting structures, and telecommunication structures; and the Transportation Products segment builds inland barges, fiberglass covers, winches, marine hardware, and other industrial equipment.